Nanostics Inc

Nanostics Inc. has developed ClarityDX Prostate, a machine-learning-enabled biomarker-based test for prostate cancer screening in men aged 40 to 70. The test stands out for its ease of integration into existing clinical workflows worldwide, providing fast and more accurate (3-4x) results at a lower cost (it does not re

Based, Nanostics Inc works in cancer.

Profile

Nanostics Inc. has developed ClarityDX Prostate, a machine-learning-enabled biomarker-based test for prostate cancer screening in men aged 40 to 70. The test stands out for its ease of integration into existing clinical workflows worldwide, providing fast and more accurate (3-4x) results at a lower cost (it does not require additional procedures or visits). As of […]

Within the cancer space, the company focuses on its core offering rather than a broad product line.

It is recorded at the Creative Destruction Lab alumni company stage.

Website: nanosticsdx.com